The landscape of circRNAs in gliomas temozolomide resistance: Insights into molecular pathways
Non-coding RNA Research,
Год журнала:
2024,
Номер
9(4), С. 1178 - 1189
Опубликована: Май 21, 2024
As
the
deadliest
type
of
primary
brain
tumor,
gliomas
represent
a
significant
worldwide
health
concern.
Circular
RNA
(circRNA),
unique
non-coding
molecule,
seems
to
be
one
most
alluring
target
molecules
involved
in
pathophysiology
many
kinds
cancers.
CircRNAs
have
been
identified
as
prospective
targets
and
biomarkers
for
diagnosis
treatment
numerous
disorders,
particularly
malignancies.
Recent
research
has
established
clinical
link
between
temozolomide
(TMZ)
resistance
certain
circRNA
dysregulations
glioma
tumors.
may
play
therapeutic
role
controlling
or
overcoming
TMZ
provide
guidance
novel
kind
individualized
therapy.
To
address
biological
characteristics
circRNAs
their
potential
induce
TMZ,
this
review
highlighted
summarized
possible
roles
that
molecular
pathways
drug
resistance,
including
Ras/Raf/ERK
PI3K/Akt
signaling
pathway
metabolic
processes
gliomas.
Язык: Английский
Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data
CNS Neuroscience & Therapeutics,
Год журнала:
2024,
Номер
30(3)
Опубликована: Март 1, 2024
Abstract
Backgroud
Glioblastoma
multiforme
(GBM)
is
among
the
most
aggressive
cancers,
with
current
treatments
limited
in
efficacy.
A
significant
hurdle
treatment
of
GBM
resistance
to
chemotherapeutic
agent
temozolomide
(TMZ).
The
methylation
status
MGMT
promoter
has
been
implicated
as
a
critical
biomarker
response
TMZ.
Methods
To
explore
mechanisms
underlying
resistance,
we
developed
two
TMZ‐resistant
cell
lines
through
gradual
increase
TMZ
exposure.
Transcriptome
sequencing
revealed
that
alterations
histone
post‐translational
modifications
might
be
instrumental
conferring
resistance.
Subsequently,
multi‐omics
analysis
suggests
strong
association
between
H3
lysine
9
acetylation
(H3K9ac)
levels
and
Results
We
observed
correlation
expression
H3K9ac
MGMT,
particularly
unmethylated
samples.
More
importantly,
our
findings
suggest
may
enhance
transcription
by
facilitating
recruitment
SP1
factor
binding
site.
Additionally,
analyzing
single‐cell
transcriptomics
data
from
matched
primary
recurrent
tumors
treated
TMZ,
modeled
molecular
shifts
occurring
upon
tumor
recurrence.
also
noted
reduction
stem
characteristics,
accompanied
an
H3K9ac,
SP1,
levels,
underscoring
potential
role
relapse
following
therapy.
Conclusions
appears
its
sites
within
locus,
consequently
upregulating
driving
GBM.
Язык: Английский
Long Non-Coding RNAs in Malignant Human Brain Tumors: Driving Forces Behind Progression and Therapy
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(2), С. 694 - 694
Опубликована: Янв. 15, 2025
Long
non-coding
RNAs
(lncRNAs)
play
a
pivotal
role
in
regulating
gene
expression
and
are
critically
involved
the
progression
of
malignant
brain
tumors,
including
glioblastoma,
medulloblastoma,
meningioma.
These
lncRNAs
interact
with
microRNAs
(miRNAs),
proteins,
DNA,
influencing
key
processes
such
as
cell
proliferation,
migration,
invasion.
This
review
highlights
multifaceted
impact
lncRNA
dysregulation
on
tumor
underscores
their
potential
therapeutic
targets
to
enhance
efficacy
chemotherapy,
radiotherapy,
immunotherapy.
The
insights
provided
offer
new
directions
for
advancing
basic
research
clinical
applications
tumors.
Язык: Английский
Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System
Oncology,
Год журнала:
2025,
Номер
unknown, С. 1 - 9
Опубликована: Янв. 24, 2025
Introduction:
Temozolomide
(TMZ)
is
a
widely
used
chemotherapy
agent
for
the
treatment
of
malignant
gliomas
and
other
brain
tumors.
Despite
its
established
therapeutic
benefits,
there
an
ongoing
need
to
understand
better
safety
profile,
particularly
in
real-world
clinical
settings.
This
study
aimed
identify
critical
adverse
drug
reactions
(ADRs)
associated
with
TMZ
by
utilizing
FDA
Adverse
Event
Reporting
System
(FAERS)
database,
thereby
providing
valuable
insights
practice.
Methods:
We
utilized
reported
odds
ratio,
proportional
reporting
Bayesian
Confidence
Propagation
Neural
Network,
Empirical
Bayes
Geometric
Mean
as
primary
algorithms
disproportionality
analysis.
events
(AEs)
were
classified
ADRs
only
upon
meeting
criteria
set
all
four
algorithms.
To
ensure
accuracy
our
results,
we
meticulously
excluded
any
AEs
deemed
unrelated
TMZ.
Results:
From
October
2003
September
2023,
total
10,502,538
case
reports
9,073
cases
explicitly
attributed
retrieved
from
FAERS
database.
After
applying
filters,
116
ADRs,
each
corresponding
Preferred
Term
(PT),
identified
across
18
Organ
Classes
(SOCs).
The
primarily
involved
bone
marrow
suppression,
hepatotoxicity,
various
infections,
notably
Pneumocystis
jirovecii
pneumonia.
Furthermore,
analysis
not
listed
label,
including
congenital,
familial,
genetic
disorders
at
SOC
level,
well
unexpected
PT
such
seizures,
pulmonary
embolism,
sepsis.
Conclusion:
pharmacovigilance
has
significant
previously
unreported
Further
research
validation
resolution
urgently
needed
guide
application
TMZ,
ensuring
efficacy
use
treating
Язык: Английский
The epigenetic mechanisms involved in the treatment resistance of glioblastoma
Cancer Drug Resistance,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 25, 2025
Glioblastoma
(GBM)
is
an
aggressive
malignant
brain
tumor
with
almost
inevitable
recurrence
despite
multimodal
management
surgical
resection
and
radio-chemotherapy.
While
several
genetic,
proteomic,
cellular,
anatomic
factors
interplay
to
drive
promote
treatment
resistance,
the
epigenetic
component
remains
among
most
versatile
heterogeneous
of
these
factors.
Herein,
landscape
GBM
refers
a
myriad
modifications
processes
that
can
alter
gene
expression
without
altering
genetic
code
cancer
cells.
These
encompass
DNA
methylation,
histone
modification,
chromatin
remodeling,
non-coding
RNA
molecules,
all
which
have
been
found
be
implicated
in
augmenting
tumor’s
behavior
driving
its
resistance
therapeutics.
This
review
aims
delve
into
underlying
interactions
mediate
this
role
for
each
components.
Further,
it
discusses
two-way
relationship
between
heterogeneity
plasticity,
are
crucial
effectively
treat
GBM.
Finally,
we
build
on
previous
characterization
explore
specific
targets
investigated
development
promising
therapeutic
agents.
Язык: Английский
Nanofibers in Glioma Therapy: Advances, Applications, and Overcoming Challenges
International Journal of Nanomedicine,
Год журнала:
2025,
Номер
Volume 20, С. 4677 - 4703
Опубликована: Апрель 1, 2025
Despite
relentless
effort
to
study
glioma
treatment,
the
prognosis
for
patients
remains
poor.
The
main
obstacles
include
high
rate
of
recurrence
and
difficulty
passing
blood-brain
barrier
(BBB)
therapeutic
drugs.
Nanomaterials
owing
their
special
physicochemical
properties
have
been
used
in
a
wide
range
fields
thus
far.
nanodrug
delivery
system
(NDDS)
with
ability
crossing
BBB,
targeting
site,
maintaining
drug
stability
controlling
release,
has
significantly
enhanced
anti-tumor
effect,
improving
patients.
Aligned
nanofibers
(NFs)
are
ideal
materials
establish
vitro
models
microenvironment
(GME),
enabling
exploration
mechanism
cell
migration
invasion
discover
novel
targets.
Moreover,
NFs
now
widely
applications
such
as
radiotherapy,
phototherapy,
thermotherapy
immunotherapy.
absolute
dominance
anti-glioma
applications,
there
still
some
problems
further
optimization
NDDS,
impact
interactions
between
protein
corona
(PC)
on
therapy.
This
paper
will
shed
light
latest
systems
mimicking
tumor
(TME),
discuss
how
optimize
NDDS
eliminate
or
utilize
nanomedicine-PC
interactions.
Язык: Английский
The importance of the circRNA/Wnt axis in gliomas: biological functions and clinical opportunities
Pathology - Research and Practice,
Год журнала:
2024,
Номер
261, С. 155510 - 155510
Опубликована: Июль 31, 2024
Язык: Английский
Lentinan Regulates Glioma Cell Proliferation and Apoptosis by Activating p53 and Caspases Pathways
Pharmacognosy Magazine,
Год журнала:
2024,
Номер
20(4), С. 1154 - 1166
Опубликована: Май 16, 2024
Background
Gliomas
are
highly
lethal
malignancies
that
develop
in
the
central
nervous
system.
The
primary
treatment
for
gliomas
involves
surgical
resection
followed
by
chemoradiotherapy.
However,
due
to
infiltrative
growth
nature
of
gliomas,
is
often
incomplete.
Moreover,
efficacy
chemotherapeutic
drugs
constrained
their
ability
cross
blood–brain
barrier,
and
currently
utilized
agents
can
lose
effectiveness,
particularly
with
prolonged
administration.
Lentinan,
an
active
compound
Lentinula
edodes,
exhibits
various
pharmacological
activities.
Purpose
This
study
aims
investigate
anti-tumor
effects
lentinan
on
glioma
U251
cells.
Materials
Methods
Cell
proliferation
assays,
cell
fluorescence
staining,
scratch
healing
experiments,
transwell
chamber
experiments
were
conducted
assess
activity
Additionally,
quantitative
real-time
polymerase
chain
reaction
(qPCR)
Western
blot
performed
validate
mechanism
lentinan.
Results
findings
revealed
significantly
suppressed
cells,
induced
robust
apoptosis,
decreased
cells’
migration
invasion
capabilities.
Furthermore,
notably
influenced
gene
protein
expression
p53,
Bcl-2,
Cyto-c,
Bax,
Caspases,
MMP-9
Conclusion
These
suggest
may
inhibit
cells
activating
P53
caspase-related
apoptosis
pathways.
Язык: Английский
Bibliometric and visualization analysis in the field of epigenetics and glioma (2009–2024)
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Окт. 29, 2024
Glioma
represents
the
most
prevalent
primary
malignant
tumor
in
central
nervous
system,
a
deeper
understanding
of
underlying
molecular
mechanisms
driving
glioma
is
imperative
for
guiding
future
treatment
strategies.
Emerging
evidence
has
implicated
close
relationship
between
development
and
epigenetic
regulation.
However,
there
remains
significant
lack
comprehensive
summaries
this
domain.
This
study
aims
to
analyze
publications
pertaining
gliomas
from
2009
2024
using
bibliometric
methods,
consolidate
extant
research,
delineate
prospects
investigation
critical
area.
Язык: Английский
Unraveling the Role of Transcription Factor SP1 and H3K9 Acetylation in MGMT Regulation and Temozolomide Resistance in Glioblastoma Multiforme
Research Square (Research Square),
Год журнала:
2023,
Номер
unknown
Опубликована: Окт. 9, 2023
Abstract
Glioblastoma
multiforme
(GBM)
is
recognized
as
a
highly
aggressive
brain
tumor,
exhibiting
profound
resistance
to
temozolomide
(TMZ)
chemotherapy.
While
methylation
of
the
MGMT
promoter
has
been
identified
significant
factor
determining
response
TMZ,
recent
evidence
indicates
that
regulatory
mechanisms
are
multifaceted,
involving
complex
interplays
with
broader
epigenetic
and
transcriptional
landscapes.
In
this
study,
we
meticulously
developed
TMZ-resistant
GBM
cell
lines
applied
comprehensive
suite
analytical
methodologies,
including
transcriptomic
proteomic
analyses,
single-cell
profiling,
elucidate
molecular
complexities
associated
TMZ
resistance.
Our
results
demonstrate
crucial
correlation
between
increased
levels
H3K9
acetylation
(H3K9ac),
elevated
expression,
heightened
resistance,
remains
steadfast
even
in
methylated
promoters.
Simultaneously,
transcription
SP1
key
regulator,
synergizing
H3K9ac
orchestrate
transcription.
Single-cell
analysis
revealed
subtle
expression
discrepancies
among
subpopulations,
propensity
for
pathway
activity
predominantly
mesenchymal
subtype.
As
tumors
relapsed,
documented
transformation
cellular
character
GBM,
migrating
from
stem-like
state
differentiation.
This
transition
marked
by
progressive
upregulation
MGMT,
SP1,
H3K9ac.
These
findings
suggest
while
clinical
relevance
undeniable,
understanding
necessitates
focus
on
synergy
histone
modifications,
regulations,
diversity.
By
deconstructing
these
intricate
relationships,
research
enhances
our
comprehension
inherent
resilience
TMZ.
Язык: Английский